343-27-1
基本信息
骆驼蓬碱盐酸盐
水合哈尔碱盐酸盐
盐酸-7-甲氧基-1-甲基-9H-吡啶并(3,4-B)吲哚
盐酸哈尔明
罗勒生物碱
7-METHOXY-1-METHYL-9H-PYRIDO[3,4-B]INDOLE HYDROCHLORIDE
BANISTERINE HYDROCHLORIDE
BANISTERIN HCL
HARMINE HCL
HARMINE HYDROCHLORIDE
4-b)indole,7-methoxy-1-methyl-9h-pyrido(monohydrochloride
harminemonohydrochloride
HARMINE HYDROCHLORIDE HYDRATE 98%
HARMINE HYDROCHLORID
CATHARANTHIN TARTRATE
DL-ANABASINE Hydrochloride
物理化学性质
| 外观性状 | 黄色结晶粉末，可溶于甲醇、乙醇、DMSO等有机溶剂，来源于骆驼蓬。 |
| 熔点 | 265-270°C |
| 储存条件 | 2-8°C |
| 溶解度 | 溶于水（高达 25 mg/ml）。 |
| 形态 | 粉末 |
| 颜色 | off-white to pale green |
| Merck | 4616 |
| 稳定性 | 可在-20°下蒸馏水溶液保存长达3个月。 |
| LogP | 3.173 (est) |
| CAS 数据库 | 343-27-1(CAS DataBase Reference) |
| EPA化学物质信息 | Harmine hydrochloride (343-27-1) |
安全数据
| 危险性符号(GHS) |   GHS07,GHS08 |
| 警示词 | 警告 |
| 危险性描述 | H302+H312+H332-H351 |
| 防范说明 | P201-P280-P301+P312-P302+P352+P312-P304+P340+P312-P308+P313 |
| 危险品标志 | Xn |
| 危险类别码 | R20/21/22-R40 |
| 安全说明 | S22-S36 |
| 危险品运输编号 | 1544 |
| WGK Germany | 3 |
| RTECS号 | MG9450000 |
| 危险等级 | 6.1(b) |
| 包装类别 | III |
| 海关编码 | 29339900 |
343-27-1(安全特性,毒性,储运)
知名试剂公司产品信息
Harmine Hydrochloride,>98.0%(LC)(T)(343-27-1) TCI Shanghai
哈尔碱盐酸盐(水合)价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/01/25 | HY-N0737 | 哈尔碱盐酸盐(水合) Harmine hydrochloride | 343-27-1 | 50 mg | 500元 |
| 2024/01/25 | HY-N0737 | 哈尔碱盐酸盐(水合) Harmine hydrochloride | 343-27-1 | 100 mg | 800元 |
| 2024/01/16 | S3817 | 哈尔碱盐酸盐(水合) Harmine hydrochloride | 343-27-1 | 25mg | 1777.43元 |
常见问题列表
| Target | Value |
|
DYRK1A
(Cell-free assay) | 33 nM |
|
MNB
(Cell-free assay) | 149 nM |
|
DYRK1B
(Cell-free assay) | 166 nM |
|
DYRK2
(Cell-free assay) | 1.9 μM |
Harmine inhibits tau phosphorylation by DYRK1A by selected DANDYs, with an IC 50 of 190 nM. Harmine negatively regulates homologous recombination (HR) by interfering Rad51 recruitment, resulting in severe cytotoxicity in hepatoma cells. Furthermore, NHEJ inhibitor Nu7441 markedly sensitizes Hep3B cells to the anti-proliferative effects of Harmine.
It is shown that brain water content is significantly increased in the TBI group. Treatment with Harmine significantly reduces the tissue water content at 1, 3 and 5 days, compared with the TBI group. Harmine treatment significantly reduces the escape latency at 3 and 5 days, compared with the TBI group. Post-TBI administration of Harmine significantly improves the motor function recovery of the rats at 1, 3 and 5 days following TBI, compared with the TBI group without Harmine treatment. The neuronal survival rate in the Harmine-treated group is significantly increased, compared with the TBI group. Administration of Harmine results in marked elevation in the expression of GLT-1, compared with the TBI group. The administration of Harmine significantly reduces the expression of caspase 3, compared with the TBI group.